Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5 | P09917 | 3/20 | 0.51 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.49 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | MAOA | P21397 | 2/20 | 0.46 |
| ▸ | MAOB | P27338 | 2/20 | 0.46 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.45 |
| ▸ | DRD2 | P14416 | 1/20 | 0.45 |
| ▸ | PKM | P14618 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | IDO1 | P14902 | 1/20 | 0.42 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.42 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.42 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14124585 | 0.91 | GRIN2D (0.48) | ALOX5MAPTEPHX2PKMLMNA | |
| SCHEMBL2028099 | 0.91 | KCNH2 (0.48) | KCNH2MAPTMAOAMAOBPKM | |
| SCHEMBL14124574 | 0.90 | ALOX5 (0.50) | ALOX5KCNH2TP53MAPTEPHX2 | |
| SCHEMBL14124560 | 0.90 | MAPT (0.42) | TP53MAPTMAOAMAOBEPHX2 | |
| SCHEMBL1994148 | 0.89 | KIF11 (0.48) | KCNH2MAPTEPHX2SMN1; SMN2PDE3B | |
| SCHEMBL15746493 | 0.88 | SMN1; SMN2 (0.48) | TP53MAPTPKMLMNAGAA | |
| SCHEMBL1993038 | 0.84 | KCNH2 (0.49) | KCNH2MAOAMAOBDRD2LMNA | |
| SCHEMBL14124561 | 0.83 | SMN1; SMN2 (0.43) | MAPTEPHX2LMNAGAASMN1; SMN2 | |
| SCHEMBL1990653 | 0.83 | MAOB (0.49) | KCNH2MAOAMAOBDRD2PDE3B | |
| SCHEMBL12600344 | 0.82 | PKM (0.48) | KCNH2MAOAMAOBDRD2PKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140148432-A1 | Compounds for the Treatment of Neurological Disorders | BABU RUPPA POORNACHARY KAMALESH (US) | 2014-05-29 | — | — | US | disclosed |
| US-20140148432-A1 | Compounds for the Treatment of Neurological Disorders | BABU RUPPA POORNACHARY KAMALESH (US) | 2014-05-29 | — | — | US | disclosed |
| US-20140148432-A1 | Compounds for the Treatment of Neurological Disorders | BABU RUPPA POORNACHARY KAMALESH (US) | 2014-05-29 | — | — | US | disclosed |
| US-8680279-B2 | Compounds for the treatment of neurological disorders | NEUROP, INC. (US) | 2014-03-25 | — | — | US | disclosed |
| US-8680279-B2 | Compounds for the treatment of neurological disorders | NEUROP, INC. (US) | 2014-03-25 | — | — | US | disclosed |
| US-8680279-B2 | Compounds for the treatment of neurological disorders | NEUROP, INC. (US) | 2014-03-25 | — | — | US | disclosed |
| US-20120302543-A1 | Compounds for the Treatment of Neurological Disorders | NEUROP, INC. | 2012-11-29 | — | — | US | disclosed |
| US-20120302543-A1 | Compounds for the Treatment of Neurological Disorders | NEUROP, INC. | 2012-11-29 | — | — | US | disclosed |
| US-20120302543-A1 | Compounds for the Treatment of Neurological Disorders | NEUROP, INC. | 2012-11-29 | — | — | US | disclosed |
| EP-2512241-A1 | COMPOUNDS FOR THE TREATMENT OF NEUROLOGIC DISORDERS | Neurop, Inc. (US) | 2012-10-24 | — | — | EP | disclosed |
| WO-2011075537-A1 | COMPOUNDS FOR THE TREATMENT OF NEUROLOGIC DISORDERS | NEUROP, INC. (US) | 2011-06-23 | — | — | WO | disclosed |
| WO-2011075537-A1 | COMPOUNDS FOR THE TREATMENT OF NEUROLOGIC DISORDERS | NEUROP, INC. (US) | 2011-06-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120302543-A1 | Compounds for the Treatment of Neurological Disorders | GRIN2A, GRIN2B, GRIN2C | ALOX5 853/4885KCNH2 244/4885TP53 4598/4885 |
| US-20140148432-A1 | Compounds for the Treatment of Neurological Disorders | NR2C2, GRIN2C, CNR1 | ALOX5 2789/4885KCNH2 144/4885TP53 3355/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.